The FDA approved Zaynich as an intravenous treatment for complicated urinary tract infections, including pyelonephritis, in adults, according to a press release from the antibiotic’s manufacturer, Wockhardt.“The threat of drug-resistant infections is an escalating crisis, leaving clinicians with fewer tools to treat patients facing these aggressive pathogens. The FDA approval of

Wockhardt's novel antibiotic, Zaynich (cefepime and zidebactam), has received US FDA approval for complicated urinary tract infections. This breakthrough drug targets superbugs…

Wockhardts newly approved antibiotic Zaynich has the potential to transform the treatment of drug-resistant infections, according to Mahesh Patel, the scientist behind the drug.…

Wockhardt will be in focus after the US FDA approved ZAYNICH, a novel intravenous antibiotic combining cefepime and zidebactam for complicated urinary tract infections. The drug…

Zaynich (cefepime and zidebactam) is an injectable antibiotic comprising cefepime, a cephalosporin antibacterial drug and zidebactam, a non-β-lactam antibacterial and β-lactamase…

Wockhardt Receives U.S. FDA Approval for ZAYNICH™ (cefepime and zidebactam), a Novel Intravenous Antibiotic for the Treatment of Adult Patients with Complicated Urinary Tract…

NEW DELIH: The US Food and Drug Administration's approval of Wockhardt's Zaynich, a first-in-class 'breakthrough antibiotic' for severe drug-resistant infections, opens up a…

The FDA approved Zaynich as an intravenous treatment for complicated urinary tract infections, including pyelonephritis, in adults, according to a press release from the…